% | $
Quotes you view appear here for quick access.

NanoLogix, Inc. Message Board

shabby47 1324 posts  |  Last Activity: Dec 7, 2015 10:31 AM Member since: Sep 23, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Nothing more. Sorry for any disappointment, but it looks like the move is nothing to worry about either way.

  • NanoLogix is very pleased to announce that today we have been informed by Faisal Alharthi, CEO of the Nasaem AlJazira Co., that the Saudi Arabia FDA (SFDA) has approved our products for import to and use in The Kingdom of Saudi Arabia. This approval came after many months of extensive testing of our products in Saudi Arabia and diligent pursuit of the approval by the Nasaem AlJazira Co. The process required a large expenditure on the part of the Nasaem AlJazira Co., multiple trips to the United States, and multiple trips by NanoLogix management to Washington DC for required approvals from the US Department of State and the Embassy of the Kingdom of Saudi Arabia.

  • Reply to

    Nasaem Al-Jazira Website

    by nanofanboyyeahbaby Dec 18, 2014 4:08 PM
    shabby47 shabby47 Dec 18, 2014 5:53 PM Flag

    We get it. You are racist and hate women. No need to keep posting about it.

  • Reply to


    by coalpilejohnny Dec 18, 2014 2:10 PM
    shabby47 shabby47 Dec 18, 2014 5:48 PM Flag

    Wrong. It depends on his contract with the company.

  • Reply to


    by coalpilejohnny Dec 18, 2014 2:10 PM
    shabby47 shabby47 Dec 18, 2014 2:59 PM Flag

    Assignment changes hands all the time. Sure it might be a little bit odd that it was changed to Bret, but not exactly unheard of since he was listed as the sole inventor.

    It is possible that the assignment was made as a form of compensation instead of monetary compensation. It is also very possible that the invention was made on his own time, off-site, without company resources and it is rightfully his (even if many others would have given it to their company out of principle).

    This is the only one which is in his name, and there are many others out there which are not. So without knowing the details, no conclusions can be made.

  • Reply to

    New quality document

    by rayludwiczak Dec 14, 2014 8:40 PM
    shabby47 shabby47 Dec 15, 2014 5:25 PM Flag

    You are right. Any time that anybody mentions a company and "resources" it can only mean money. Thank you for correcting me from my erroneous ways.

    You really must be a treat to those around you. Is that why you spend Christmas alone?

  • Reply to

    New quality document

    by rayludwiczak Dec 14, 2014 8:40 PM
    shabby47 shabby47 Dec 15, 2014 4:15 PM Flag

    Did I say "cash resources"? No, I did not. But that would not allow you the opportunity to disparage the company so you have to make up a new meaning to my comment. It really is sick how far you go to get negative jabs in on every single post.

  • Reply to

    New quality document

    by rayludwiczak Dec 14, 2014 8:40 PM
    shabby47 shabby47 Dec 15, 2014 12:44 PM Flag

    Good to see the old products are still updating. For a while I was wondering if they had put all their resources into the n-assay.

  • You can watch the bid jump up by the second higher and higher until a seller is found. seems that somebody wants in

  • NanoLogix has received notification of BNP patent grant from the European Union. Grant date was 11/26/2014. This is a welcome addition to the NanoLogix patent portfolio, providing intellectual property protection in the EU for the first time for any NanoLogix product. Interested shareholders should note the length of time from date of application to date of patent grant. Over 6-1/2 years of legal and financial resources went into this achievement. The company thanks Gwen Acker Wood, PhD, JD, of ACKER WOOD Intellectual Property Law, LLC, for her outstanding work on this and other patents pending and granted.

    EUROPEAN PATENT GRANT CERTIFICATE _____________________________________________________________
    Applicant Nanologix, Inc. Application Date 24 March 2008 Grant No 2134857 Grant Date 26 November 2014 Expiry Date 24 March 2028 (If renewed as set out below) Title Detection and identification of microorganisms on transparent permeable membranes Priority Application(s) United States of America Application No. 60/896321 filed on 22nd March 2007 Renewal Fees Due Annually in each designated state in March

  • Reply to

    UPDATED: Valuation

    by nanofanboyyeahbaby Dec 9, 2014 3:29 PM
    shabby47 shabby47 Dec 9, 2014 3:58 PM Flag

    And AMZN needs to make something like $700B in order to justify its price.

    A board favorite around here, AXDX would need somewhere around $800M instead of the $50K or whatever it makes.

    Your "valuation" is pointless.

  • Reply to


    by masterjamerson Dec 3, 2014 3:57 PM
    shabby47 shabby47 Dec 3, 2014 4:06 PM Flag

    Maybe you can have it catered. Know anyone good?

  • Reply to

    Reaction to financials

    by selectequities101 Dec 3, 2014 2:00 PM
    shabby47 shabby47 Dec 3, 2014 2:43 PM Flag

    That was 95% of their bashing. "Where are the financials? What are they hiding? They must be hemorrhaging money if they won't release numbers." etc.

    Now they have nothing left. Give them 24 hours and they will be back to personal attacks on the CEO.


  • Reply to

    Update on N-Assay (V) for rapid virus detection

    by shabby47 Oct 29, 2014 11:42 AM
    shabby47 shabby47 Oct 29, 2014 1:57 PM Flag

    This was provided to everyone who signs up for their email updates. It was written by the company themselves and sent to everyone on their list.

  • This update is related to the Press Release issued by NanoLogix 14 October 2014

    At a minimum, the press release has been covered with stories in the Washington Post Innovation blog, The Warren Tribune Chronicle, Warren, Ohio; The YoungstownCBS/Fox/ABC/NBC Youngstown, Ohio affiliated television stations; NBC/Pittsburgh, Fox/Tampa television.

    As a result, NanoLogix N-Assay (V) is currently being evaluated by pharmaceutical companies for use as a simple rapid diagnostic tool for viruses for use in remote locations in close proximity to outbreak events. Nanologix this week signed two Mutual Confidentiality Agreements with US corporations interested in their technology.

    Given the key word "Confidentiality", further information will be released when and if dictated by events.

  • Reply to

    Ebola PR

    by shabby47 Oct 14, 2014 9:36 AM
    shabby47 shabby47 Oct 14, 2014 9:37 AM Flag

    much more of a hopeful statement, not sure what to think of it, but I am sure that many here will have very negative thoughts...

  • shabby47 by shabby47 Oct 14, 2014 9:36 AM Flag

    HUBBARD, Ohio--(BUSINESS WIRE)--NanoLogix Inc. (NNLX), an innovative biotechnology company in Northeastern Ohio announces that it is configuring its N-Assay Rapid diagnostic kits for both Ebola Virus and Enterovirus detection and identification. NanoLogix CEO Bret Barnhizer stated, “The Company has been aware of the virus detection capabilities of the technology since the N-Assay development. Viruses viewed as public health concerns prior to Ebola and Enterovirus were Influenza, the common cold, and HIV, none of which have an immediate or near-immediate threat of mortality. Until recently, NanoLogix has been focused solely on the use of their N-Assay kit for bacteria detection and identification. Now, with the recent outbreaks of both Ebola and Enterovirus there is an immediate need for configuration of the N-Assay for viruses. NanoLogix facilities are not designed for work on viruses, for this specific project we are seeking a corporate partner with the facilities necessary to bring the new N-Assay (V) to the market as quickly as possible. We consider this a matter of national security and an emergency priority. We are in discussions with potential partners, positioned with strong ties to the US government, who understand the serious threat these viruses represent.”

    The NanoLogix N-Assay (V) ELISA is one of six technologies that may be used for virus detection and identification, the N-Assay (V) has unique qualities that contribute to both its rapid detection capability and long term durability that should be attractive to personnel in both developed and remote locations interested in a screening test that may provide results for Ebola or other viral threats in 30 minutes to a few hours.

    Supporting information on the N-Assay (B), used for bacterial detection and identification and evidence of the capabilities of one version of the technology can be found by following this link:

    etc. etc. look online for it

  • shabby47 by shabby47 Sep 29, 2014 9:44 AM Flag

    See the internet for it since yahoo keeps having problems with me pasting it here.

  • Reply to

    Who's the

    by rayludwiczak Sep 19, 2014 3:00 PM
    shabby47 shabby47 Sep 19, 2014 3:26 PM Flag

    Jumped right past a bid I had in. My bid still higher than what is being shown too. Awesome.

  • Reply to

    Not only are the longs absent here,BUT

    by parentsgratae Sep 11, 2014 9:11 AM
    shabby47 shabby47 Sep 11, 2014 4:45 PM Flag

    real good use of your time. You must have a thrilling life

0.07-0.02(-19.21%)2:47 PMEDT